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Catholic University of Argentina, Buenos Aires, ArgentinaABSTRACT Human phospholipid scramblase 1 (SCR) catalyzes phospholipid transmembrane (flip-flop) motion. This protein
is assumed to bind the membrane hydrophobic core through a transmembrane domain (TMD) as well as via covalently bound
palmitoyl residues. Here, we explore the possible interaction of the SCR TMD with cholesterol by using a variety of experimental
and computational biophysical approaches. Our findings indicate that SCR contains an amino acid segment at the C-terminal
region that shows a remarkable affinity for cholesterol, although it lacks the CRAC sequence. Other 3-OH sterols, but not ste-
roids lacking the 3-OH group, also bind this region of the protein. The newly identified cholesterol-binding region is located partly
at the C-terminal portion of the TMD and partly in the first amino acid residues in the SCR C-terminal extracellular coil. This
finding could be related to the previously described affinity of SCR for cholesterol-rich domains in membranes.INTRODUCTIONHuman phospholipid scramblase 1 (SCR) is an endofacial
plasma transmembrane protein that has reported to function
in the process of apoptosis as a nonspecific translocator
of phosphatidylserine to the membrane outer monolayer
(1–3). However, a number of studies (4–7) have suggested
that the physiological role of this protein could in fact be un-
related to membranes, with SCR acting instead as a modu-
lator of gene expression. SCR structure has not yet been
resolved by crystallographic analysis, but experimental evi-
dence suggests that scramblases present a structural dimor-
phism in the cell. SCR would exist in a palmitoylated form
in plasma membrane caveolae-like, cholesterol (Chol)-rich
lipid domains (8), where they would partition together
with caveolin-1 and epidermal growth factor receptor
(EGFR) (9), and in a nonacylated form in the nucleus, where
they would play a role as a transcription factor with impor-
tant functions in cellular proliferation and differentiation
(4,5), including tumor suppression (6). Bateman et al. (7)
proposed a structural model for scramblases according to
which palmitoylation, rather than the transmembrane
domain (TMD), would constitute the main membrane
anchorage for these proteins. However, recent data from
our laboratory and others have cast doubt on this assertion.
Although mutant SCR lacking the TMD is still able to bind
lipid bilayers (10), it has lost functional scramblase activity
(11,12). Moreover, the isolated TMD binds and becomes in-
serted into lipid bilayers with great affinity (13).Submitted May 1, 2014, and accepted for publication July 22, 2014.
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0006-3495/14/09/1383/10 $2.00In this study, we address the affinity of SCR for Chol
in relation to the SCR trafficking to Chol-rich membrane
domains, and the insertion of the TMD in these regions
(Fig. 1 A). Chol recruitment amino acid consensus
(CRAC) is a well-known Chol-binding domain in proteins,
with the consensus pattern [L/V]-[X](1-5)-[Y]-[X](1-5)-
[R/K]. This pattern is broadly conserved in many membrane
proteins (14–16), although mutation of some of these amino
acids does not necessarily entail the loss of Chol interaction.
The human scramblase family contains a CRAC domain
sequence at the C-terminus of the TMD, but in the first
member of the family the consensus is not conserved
(Fig. 1 B). Another consensus sequence, named CARC, con-
stitutes exactly the reverse sequence of the CRAC domain,
with an additional option for the central aromatic amino
acid, which could be either Y or F (17). SCR contains the
combination of basic arginine (at position X3), aromatic
phenylalanine (X11), and aliphatic leucine (X12) residues
in TMD found in the CARC motif, but the disposition of
arginine does not fulfill the criterion of the CARC algorithm
that five residues must separate the basic from the aromatic
amino acid. In addition to the CRAC and CARC sequences,
an important factor in protein-Chol binding is the three-
dimensional orientation of the amino acid side chains with
respect to the a/b faces of the sterol. Many tilted peptides,
such as a-synuclein (18) and the TM glycoprotein gp41 of
HIV-1 (19), bind Chol with a very exothermic energy of
interaction, and these affinities are orientational in the space
rather than sequence based.
Here, we conducted experimental and computational
studies to examine the interaction of SCR and its TMD
with lipid monolayers and bilayers of varying lipidhttp://dx.doi.org/10.1016/j.bpj.2014.07.039
FIGURE 1 (A) SCR domains and sequence-derived peptides: DNA-bind-
ing domain (pink), Cys-rich domain (yellow), nuclear localization signal
(green), calcium-binding domain (blue), and TMD (red). (B) Representa-
tion of the human phospholipid (hPL) SCR family putative TMD sequence.
hPL SCRs 2, 3, and 4 contain a CRAC motif ([L/V]-[X](1-5)-[Y]-[X](1-5)-
[R/K]) localized at the C-terminal end of the predicted transmembrane helix
(amino acids in red), whereas SCR presumably is the result of several mu-
tations (in green), such as the polar amino acid (serine) instead of a posi-
tively charged amino acid (arginine or lysine), and two phenylalanines
in different positions, which appear as tyrosines in the rest of the family
sequences. Thus, neither the CRAC nor the CRAC-like sequence ([L/V]-
[X](1-5)-[F]-[X](1-5)-[R/K]) is completed in SCR TMD. Sequence informa-
tion was taken from UNIPROT. Sequences were aligned according to
Sahu et al. (3) and Bateman et al. (7).
1384 Posada et al.composition, including different steroids. We focused on the
recombinant, nonpalmitoylated protein and peptides derived
from the C-terminus sequence: TM19, which comprises the
TMD sequence, and TM31C, which comprises the TMD
plus the extracellular coil sequence (Fig. 1 A). Our findings
support the idea that a sequence in the C-terminal region of
SCR, spanning part of the TMD and part of the adjacent
extracellular coil, binds 3-OH sterols with high specificity.
This may be related to the affinity of SCR for Chol-rich
membrane domains.MATERIALS AND METHODS
Materials
TM31C (aa sequence: KMKAVMIGACFLIDFMFFESTGSQEQKSGVW)
and TM19 (aa sequence: KMKAVMIGACFLIDFMFFE) were synthe-
sized and purchased from PolyPeptide Group Laboratories (Strasbourg,
France) and stored at 20C in powder. For the different experiments,
the peptides were dissolved in DMSO (Sigma) or HFIP (Fluka) immedi-
ately before use. All phospholipids and sterols were obtained from Avanti
Polar Lipids (Birmingham, AL), and 8-aminonaphtalene-1,3,6-trisulfonic
acid sodium salt (ANTS) and p-xylenebis(pyridinium) bromide (DPX)
were obtained from Invitrogen (Life Technologies, Carlsbad, CA). The
polyclonal C-terminal anti-scramblase antibody was obtained from Onco-
gene (Cambridge, UK) and the monoclonal N-terminal anti-scramblase
antibody was obtained from Abcam (Cambridge, UK). Horseradish perox-
idase (HRP)-linked anti-rabbit and anti-mouse antibodies were obtained
from New England Biolabs (Ipswich, MA); 1-lauroyl-2-(1-pyrenebu-
tyroyl)-sn-glycero-3-sphingomyelin (pyrene-SM) was synthesized as
described in Muller et al. (20); and 1-oleoyl-2-{6-[(7-nitro-2-1,3-benzoxa-Biophysical Journal 107(6) 1383–1392diazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphoserine (C6-NBD-PS)
was obtained from Avanti Polar Lipids (Birmingham, AL). The Chol oxi-
dase/peroxidase kit was obtained from Biosystems (Barcelona, Spain).
All other reagents were of analytical grade.Solid-phase binding assay
A screening dot-blot analysis was performed to assess the sterol analog
affinities of TM31C and SCR (21). Lipids were dissolved in methanol/chlo-
roform/water (2:1:0.8 v/v/v) at a final concentration of 800 mM, and 1 ml
was spotted on a Hybond-C extra membrane and left for 1 h to let the lipid
dry. After blocking with 0.75% skimmilk in PBS for 1 h, the membrane was
incubated for an additional hour with the peptide TM31C or with the re-
combinant protein SCR (500 nM final concentration), also in PBS. The
membrane was then washed several times, followed by 1 h incubation of
the anti-scramblase C-terminal and N-terminal antibody, respectively
(1:1000). The blot was washed several times with PBS, pH 7.4, and incu-
bated for 1 h with an HRP-linked anti-rabbit (for peptide) and anti-mouse
antibody (for protein) (1:2000). After final washes to eliminate the non-
bound secondary antibody, the blot was developed on a Curix 60 processor
(AGFA, Belgium) using the Amersham Hyperfilm ECL (GE Healthcare,
UK). The intensity of the sample signal was measured with a densitometer
GS-800 (Bio-Rad, Stockholm, Sweden).Langmuir balance measurements
TM31C-induced changes in surface pressure at the air/water interface and
peptide-lipid monolayer interactions were studied at 25C using a 1.25 ml
multiwell Delta Pi-4 system (Kibron, Helsinki, Finland). Monolayers were
formed by spreading a small amount of the lipid mixture made of POPC and
increasing concentrations of Chol in a chloroform/methanol (2:1 v/v) solu-
tion on top of the assay buffer until the desired initial surface pressure was
attained. Then, 3 mM peptide dissolved in DMSO (<0.5% of total volume)
was individually injected with a micropipette through a hole connected to
the subphase, and its surface activity was followed by means of surface
pressure changes with constant stirring.Vesicle content efflux measurements
Large unilamellar vesicles (LUVs) were prepared in assay buffer in the
presence of ANTS and DPX in a 1:3.6 ratio. LUVs were prepared by
extruding multilamellar vesicle (MLV) suspensions through polycarbonate
filters (0.1 mm pore diameter). The lipid suspension was then passed
through a Sephadex PD-10 column to discard nonencapsulated dye. Vesicle
content efflux or leakage was measured at 23C in a Fluoromax lumines-
cence spectrometer by following ANTS externalization after peptide (dis-
solved in DMSO) addition in a 1:50 mol ratio. ANTS was excited at
355 nm and emission was recovered at 530 nm using a cutoff filter at
470 nm. Initial vesicle suspension was used as the 0% fluorescence signal,
and 100% fluorescence was obtained after breakdown of the vesicles by
addition of 1 mM Triton X-100 (22,23).Differential scanning calorimetry
Differential scanning calorimetry (DSC) measurements were performed us-
ing a VP-DSC high-sensitivity scanning microcalorimeter (Microcal,
Northampton, MA). For preparation of peptide-MLVs, the appropriate
amounts of either pure SOPC (0.5 mM final concentration) or SOPC/
Chol 1:1 (2.5 mg/ml final concentration) (16) in chloroform/methanol
(2:1 v/v) and peptide in HFIP were mixed and the solvent was evaporated
exhaustively. The MLVs were then prepared by slowly hydrating the pep-
tide-containing lipid film with assay buffer at a temperature above the
lipid-phase transition temperature, with continuous stirring with a glass
Cholesterol Binding to scramblase 1385rod followed by vigorous vortexing of the sample at 50C. The samples
were then carefully degassed before measurements were conducted. The
assay buffer was scanned as a background. The scan rate was 90C/h. Sam-
ples were scanned several times to ensure the reproducibility of the endo-
therms. Data were analyzed using ORIGIN software provided by
MicroCal. The final volume of the cell was 0.5 ml. The SOPC concentration
was measured with a molybdate assay, and the Chol concentration was
measured with the use of a Chol oxidase/peroxidase kit.In silico studies of Chol-SCR interactions
Molecular modeling studies were performed using the Hyperchem 8 pro-
gram (ChemCAD, Obernay, France). A model of the FLIDFMFFES
TGSQE peptide was first obtained in vacuo and then merged with Chol.
Various starting conditions were assayed and only the one that led to the
highest energy of interaction was selected. Geometry optimization of the
Chol/SCR complex was achieved using the unconstrained optimization
rendered by the Polak-Ribie`re conjugate gradient algorithm (24). Molecu-
lar-dynamics simulations were then performed for iterative periods of 1 ns
in vacuo with the Bioþ (CHARMM) force field (25). The energy of inter-
action was determined with the Molegro Molecular Viewer (26).SCR purification and reconstitution into
lo-containing LUVs
SCR was overexpressed as an MBP-fusion protein and purification was per-
formed essentially as described previously by Zhou et al. (2). For the recon-
stitution assay, a mixture of DOPC/eSM/Chol (2:1:1 or 1:1:1 mol ratio),
POPC/PS/Chol (9:1:3.3 mol ratio), or PC/PS (9:1 mol ratio) was dried un-
der a stream of nitrogen and resuspended in 20 mM Tris (pH 7.4), 100 mM
KCl, and 0.1 mM EGTA. The protein samples to be reconstituted were
added to the liposomes at a 5 mM final lipid concentration in the presence
of 30 mM OG and dialyzed overnight at 4C in a buffer containing Bio-
Beads SM-2 (1 g/l). A sucrose gradient was performed afterward to isolate
reconstituted from nonreconstituted proteins (12,27).Flip-flop assay
Proteoliposomes (100 mM final lipid concentration) were transferred to a
stirred fluorescence cuvette at 37C, and 5 mol % pyrene-SM was added
to label the vesicles externally (12,20). Initial fluorescence was recorded
and 5 mM calcium was added. Fluorescence was monitored for 80 min
(lex¼ 344 nm, lem¼ 380–520 nm) in an Aminco Bowman Series 2 spectro-
fluorometer (Rochester, NY) and the decay of the Iex/Imon ratio was attrib-
uted to a calcium-induced change of the py-SM position from the outer to
the inner monolayer, promoted by the reconstituted proteins (20).
Alternatively, proteoliposomes were labeled with externally added 0.1%
C6-NBD-PS and the sample was incubated for 30 min on ice to ensure com-
plete incorporation of the probe into the liposomes. Phospholipid flip-flop
was initiated by adding 5 mM Ca2þ followed by incubation at 37C. At
different time intervals, an aliquot was taken and immediately added to a
stirred cuvette (5-fold dilution) at 23C in an Aminco Bowman Series 2
spectrofluorometer, and the reaction was stopped by addition of 5 mM
sodium dithionite (28). Flip-flop was quantified by comparing NBD fluores-
cence before (F0) and after (Fx) bleaching by the addition of dithionite, ac-
cording to the equation F (%) ¼ (Fx/F0)  100.FIGURE 2 Solid-phase binding assay. Dot blots of TM31C (A) and SCR
(B) binding to Chol (#1) and different analogs: cholestanone (#2), ergos-
terol (#3), 5a-cholestane (#4), 7-dehydrocholesterol (#5), Chol-one (#6),
and coprostanol (#7). (C and D) The results are presented in decreasing
order of peptide (C) and SCR (D) binding to sterol analogs. The binding
indicates the importance of the alcohol group in ring A for interaction
with the scramblase TMD.RESULTS
Lipid overlay assay
Both the SCR protein and the TM31C peptide were studied
using a solid-phase binding assay, which enables rapid iden-tification of the lipid ligands with which proteins interact. In
this case, Chol and six steroid analogs were spotted onto a
nitrocellulose membrane and incubated with the protein/
peptide samples. The immunoblotted membranes are shown
in Fig. 2, A and B. The protein and peptide exhibit a remark-
able preferential binding for sterols containing the polar
alcohol group in ring A, which seems to be a major struc-
tural requirement for interaction with the scramblase TMD.
Binding quantitation is displayed in Fig. 2, C and D, for
TM31C and SCR, respectively. In both cases, Chol (#1),
ergosterol (#3), and 7-dehydrocholesterol (#5) are the ste-
rols for which SCR and TM31C exhibit the strongest inter-
action, and both show a lower binding for coprostanol (#7),
which includes the alcohol group in ring A but lacks the
double bond in ring B of Chol. Apparently this absence of
a double bond lowers the scramblase TMD’s affinity for
the sterol. Finally, in both cases, the steroids that exhibited
the lowest protein/peptide binding were cholestanone (#2)
and cholestenone (Chol-one) (#6), which include a ketone
group instead of an alcohol group in ring A, followed by
5a-cholestane (#4), which lacks any oxygenated chemical
group in ring A and the double bonds in ring B. Hence,
the solid-phase binding assay indicates a strong affinity be-
tween SCR TMD and Chol or similar C3-OH sterols.Peptide interaction with mono- and bilayers
containing Chol
To substantiate the lipid overlay assays that suggested a
scramblase TMD affinity for Chol, we carried LangmuirBiophysical Journal 107(6) 1383–1392
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into pure POPC and POPC/Chol lipid films. TM31C peptide
is a powerful tool for exploring SCR TMD affinity for Chol
in model and cell membranes, and is more manageable than
the native protein. Insertion of TM31C into PC monolayers
was previously reported (13), with a critical surface pressure
pc (the maximum surface pressure beyond which no peptide
insertion occurs) at 33 mN/m. At p0 ¼ 245 0.5 mN/m (the
initial monolayer pressure), a Dp (surface pressure increase)
of 3.9 5 0.17 mN/m was reported. With the addition of
increasing concentrations of Chol to PC monolayers, a
dual effect is detected (Fig. 3 A): 1) TM31C shows greater
affinity for monolayers containing up to 20 mol % Chol
than for pure PC, even if the mean molecular area decreases
under these conditions (29). Due to the increasing presence
of Chol, monolayers become more compressed at the same
p0, impeding peptide insertion and diminishing Dp, but the
affinity for Chol nonetheless increases. At 20 mol % Chol,
Dp rises to 5.9 5 0.18 mN/m with a mean molecular area
of 56 A˚2, which is 11 A˚2 lower than observed for pure PC
monolayers. 2) From this point on, at 30–50 mol % Chol,
peptide insertion into monolayers decays, probably owing
to the high packing of the lipid molecules, which hampers
the peptide affinity for Chol. The slope of the time courses
of peptide-induced p changes correlates with the observed
equilibrium Dp (Fig. 3 A). Thus, the Langmuir balance
data are in agreement with the above binding data obtained
with both the peptide and the protein, showing that scram-
blase TMD has a large and measurable affinity for Chol
when it is in solid phase or included in a monolayer lipid
film.
As previously reported, TM31C in Chol-containing LUV
bilayers can promote a large peptide-induced release of ve-
sicular aqueous contents (see, e.g., the POPC/pSM/Chol
1:7:2 (lo þ so) composition (13)). When Chol was replaced
with Chol-one, an abrupt decrease was observed in both the
extent of release and the initial efflux rate (Fig. 3, B and C).
Thus, the SCR TMD’s affinity for Chol in solid phase andBiophysical Journal 107(6) 1383–1392mono- or bilayers is confirmed. In the latter case, it is
important to remember that Chol-one cannot form lo do-
mains in vesicles as does Chol, suggesting that the presence
of these domains or the presence of a phase boundary is
also important. Domain boundaries would favor peptide
insertion and accommodation in the bilayer and promote
leakage.TM31C-induced Chol phase separation detected
by differential scanning calorimetry
Calorimetric studies were performed to observe scramblase
TMD behavior in SOPC/Chol 1:1 (mol ratio) bilayers ac-
cording to a previously described method (16,30). CRAC-
motif-containing peptides, such as the caveolin-1 peptide,
can alter membrane properties, forming Chol-rich domains
by forcing the sterol beyond its solubility limit and thus
causing formation of Chol crystals (anhydrous Chol). Due
to single-residue mutations, scramblase TMD lacks the
CRAC sequence (Fig. 1 B), but nonetheless displays a ten-
dency to interact with Chol. We therefore developed an
experiment to quantify the interaction thermodynamically.
In addition to TM31C, we used TM19, a peptide that com-
prises only the putative TMD sequence (Fig. 1 A).
Fig. 4 A shows the heating endothermic phase transitions
for the SOPC/Chol lipid mixture and mixtures with
increasing concentrations of TM31C. In the pure lipid sys-
tem, there is no detectable endotherm near 36C (thermo-
gram 1), but a broad endotherm starts to appear in the
presence of 2.5 mol % TM31C (thermogram 2). Increasing
the peptide concentrations up to 7.5 mol % results in the
appearance of an even more prominent and cooperative
endotherm at 36C (thermograms 3 and 4), with the conse-
quent exothermic peak at 24C observed in the cooling
scans (not shown). These signals can be attributed to the
polymorphic transition of anhydrous Chol crystals extracted
from the lipid mixture by the peptide. In contrast, TM19
seems to initially promote a modest anhydrous CholFIGURE 3 (A) Surface pressure measurements
of TM31C in PC/Chol monolayers. The increase
in surface pressure (C) is shown after insertion of
TM31C into lipid monolayers (p0 ¼ 24 5
0.5 mN/m) made of PC and increasing concentra-
tions of Chol; the calculated slopes from the time
traces are represented by B, dotted line. Experi-
mental data are fitted to a polynomial function
(degree ¼ 2). Symbols correspond to the mean 5
SDs of four to six independent measurements. The
mean molecular areas (B, dashed line) were taken
from Li et al. (29) to show the increased monolayer
packing. (B and C) ANTS-DPX vesicle content
efflux. (B) Time course of TMC31-induced release
of intravesicular aqueous contents for POPC/PSM/
Chol (1) and POPC/PSM/Chol-one (2) 1:7:2 com-
position. (C) TM31C-induced total release (black
bars) and corresponding initial rates (white bars).
FIGURE 4 (A and B) DSC of pure SOPC/Chol
1:1 (mol:mol) (thermogram 1) and the same lipid
mixtures with 2.5 mol % (2A or 2B), 5 mol %
(3A or 3B), and 7.5 mol % (4A or 4B) TM31C
or TM19, respectively. Scans are offset along
the y axis for clarity of presentation. The scan
rate was 1.5C/min from 10C to 50C. The lipid
concentration was 4 mM in 20 mM PIPES (pH
7.4), 150 mM NaCl, 1 mM EDTA. (C) Heating-
cooling scans of 5 mol % TM31C- (thermograms
1 and 2) or TM19- (thermograms 3 and 4) induced
changes when inserted into SOPC/Chol 1:1 (mol
ratio). (D) DSC measurements of pure SOPC (ther-
mogram 1) and mixtures with 7.5 mol % TM31C
(thermogram 2) or TM19 (thermogram 3). Only
cooling scans are shown in D.
Cholesterol Binding to scramblase 1387formation in vesicles (Fig. 4 B, thermogram 2), but from that
point on (Fig. 4 B, thermograms 3 and 4), at 5 and 7.5 mol
%, crystal formation does not occur and the endotherms do
not show any further changes (see Table 1).
The behavior of short and long peptides with other lipid
compositions, such as pure pSM and pure DPPC, was
checked previously (13) and the obtained endotherms
were virtually the same for both peptides. Thus, the endo-
thermic differences obtained with SOPC/Chol membranes
in this case are apparently the result of the lack of the C-
ter extracellular coil in TM19 peptide, suggesting that this
segment is a crucial element for the interaction with Chol.
Peptides that preferentially interact with Chol-rich do-
mains sequester Chol, leaving other parts of the membrane
depleted of Chol. As a consequence, the Chol-poor regions
exhibit a higher enthalpic and cooperative transition of the
phospholipid partner. In contrast, when peptides interactTABLE 1 Peptide induction of anhydrous cholesterol
crystallite formation
TM31C (long peptide) TM19 (short peptide)
Parameters 2.5 mol %5 mol %7.5 mol %2.5 mol %5 mol %7.5 mol %
DH (cal/mol) 290 623 864 131 149 189
Tm (
C) 38.7 36.4 35.6 37.6 38 37.8
T1/2 (
C) 4.4 1.9 1.8 4.2 4.1 4.2
The thermodynamic correspond to the anhydrous cholesterol endothermic
phase transition near 36C.preferentially with Chol-depleted regions, the cooperativity
of the phospholipid phase transition decreases, resulting in
a broader and lower transition enthalpy. We performed se-
rial cooling scans from 50C to 1C to discern the peptide
location in Chol-depleted or Chol-rich domains (Fig. 4 C).
The lack of an SOPC transition at 6C indicates that TM19
partitions mainly into Chol-depleted domains and is there-
fore unable to accomplish the large formation of Chol crys-
tals that TM31C elicits. However, even the long peptide
does not give rise to an increase in the SOPC transition
enthalpy, possibly because this peptide partitions, to some
extent, into both Chol-rich and Chol-depleted domains.
Traditionally, SCR has been reconstituted in Chol-free ves-
icles, and the possibility of simultaneous partitioning was
evidenced by the TM31C peptide-induced widening of
the transition of pure SOPC, just as observed for TM19
(Fig. 4 D).
From this series of DSC experiments, we conclude that
even in the absence of a CRAC sequence, TM31C is
more effective at promoting the formation of Chol-rich do-
mains than the shorter peptide TM19, which comprises
only the putative TMD domain. These data suggest that
the C-terminal extracellular amino acids contribute to the
interaction with Chol. Long TMDs favor insertion into lo
domains, avoiding the mismatch that occurs upon insertion
into ld domains (31,32). For instance, protein TMDs
anchored to Golgi membranes have an average length ofBiophysical Journal 107(6) 1383–1392
1388 Posada et al.15 aa, whereas TMDs of proteins in the plasma membrane,
with 3-fold more Chol, exhibit an average length of ~22 aa
(33). In the case of SCR, amino acids such as Ser, Thr, and
Gly can be found in the membrane interface in contact with
lipid headgroups (34). Additionally, the two snorkeling Lys
found at the beginning of the TMD sequence (35) could
also favor the protein partitioning into Chol-rich domains.
The 19 aa length of SCR TMD does not fulfill the length
requirement for avoiding the abovementioned mismatch,
and thus the SCR C-terminal juxtamembrane segment’s
interaction with Chol could favor protein insertion into lo
domains.In silico studies of Chol-SCR interactions
We used several starting conditions and conducted a series
of molecular modeling simulations on a short sequence
[298FLIDFMFFESTGSQE311] that includes the last C-ter-
minal amino acids of the putative TMD and the first amino
acids of the protein C-terminal extracellular coil, which
appear to be involved in the interaction with Chol. A
detailed analysis of the energy of interaction of Chol and
this sequence showed that the interaction complex involves
essentially eight residues—five in the SCRTMD (F298, L299,
I300, M303, and E306) and three in the protein C-terminal jux-
tamembrane positions (S307, S310, and Q311)—for a total
energy of interaction of 64.39 KJ.mol1 (Fig. 5 A).
Surprisingly, the last three Fs of the TMDs, which theo-
retically might interact through their aromatic lateral
chains with the lipid rings, do not interact with Chol. Mo-
lecular modeling studies have shown that the remaining
sequence can have a good fit for Chol, as illustrated in
Fig. 5, B and C. The synthetic peptide TM19 ending in
Glu306 would lose the energies of interaction of S307,
S310, and Q311. As a result, Chol could not interact properly
with Glu as a terminal residue, as experimentally observed
(Fig. 4 B).Biophysical Journal 107(6) 1383–1392SCR reconstitution in ld- and lo-domain-
containing membranes
The recombinant purified protein could be reconstituted in ld
membranes (e.g., PC/PS 9:1 (mol/mol) (12)) or in lo-con-
taining membranes (e.g., DOPC/PSM/Chol 2:1:1 or 1:1:1
(mol ratio); Fig. 6, A and B). After reconstitution into lo-con-
taining LUVs made of PC/SM/Chol 2:1:1 (mol ratio), flip-
flop activity was assayed according to the pyrene excimer
method (20) and the NBD-dithionite method (28). Freshly
synthesized pyrene-sphingomyelin (py-SM) was used, and
protein reconstituted in ld PC/PS 9:1 LUVs was used as a
positive control for lipid scrambling.
The data in Fig. 6 C show that for PC/PS 9:1 and PC/
SM/Chol 2:1:1, in the presence of SCR, the proportion
of pyrene excimer/monomer decreased, particularly in
the first 30 min after 5 mM Ca2þ addition, which fully
activated the protein. This is taken as an indication of
transmembrane lipid motion, or flip-flop (12). The protein
reconstituted in lo-containing membranes was expected to
promote faster or more extensive py-SM translocation due
to the presence of Chol, but in fact the scrambling motion
was somewhat lower than that observed for the protein re-
constituted in pure ld phase. The Chol-ordering effect in
the vicinity of the SCR might inhibit the translocation
mechanism. SCR was reconstituted in the POPC/PS/Chol
9:1:3.3 (mol ratio) composition as well, to exclude the
possibility that the lower translocation rate recorded for
the 2.1:1 composition could be due to the lack of a nega-
tive charge in the membrane, and the scrambling rate
was found to be the same as in the 2:1:1 composition
(Fig. 6 C).
Similar results were obtained for SCR reconstituted in
PC/PS 9:1 and PC/SM/Chol 2:1:1 compositions with the
NBD-PS probe (Fig. 6 D). Zhao et al. (36) suggested that
cysteines in the SCR N-terminal structure could be respon-
sible for the decreased activity of the recombinant protein as
compared with the native form. Thus, it appears that CholFIGURE 5 Docking of Chol on hPL SCR. A
short part of TM31C, [298FLIDFMFFESTGSQ311],
contains the highest enthalpic interaction with
Chol. (A) Detailed analysis of the energetics of
Chol interaction with the protein TMD and other
surrounding amino acids that presumably are
involved in the interaction. (B) Surface view of
the complex, with important amino acid side
chains presented as interacting with the sterol.
The TMD amino acid M303 is represented as Met-
16, which interacts with the Chol ring structure,
and the C-terminal coil amino acids S309 and
Q311, which interact with the small polar alcohol
headgroup, are represented as Ser-23 and Gln-24
respectively. E306, at the end of TMD (which is
not represented), contains the highest enthalpic
interaction with Chol. (C) Overall illustration of
the interaction of scramblase TMD C-ter coil (in
blue) and Chol.
FIGURE 6 (A) Dot blots of the fractions recov-
ered from the sucrose gradient (27) (fractions
1–4, samples recovered from top to bottom of the
sucrose gradient). The yield of protein reconstitu-
tion into PC/SM/Chol 2:1:1 and 1:1:1 vesicles
was virtually the same (~50% of SCR successfully
reconstituted). (B) SCR quantification in each
recovered fraction when reconstituted in PC/SM/
Chol 2:1:1 vesicles (gray bars) or PC/PS 9:1 vesi-
cles (black bars). The recovered top fraction was
used for the flip-flop assay. White bars correspond
to pure ultracentrifuged protein. (C and D) Influ-
ence of Chol on py-SM (C) and NBD-PS (D)
transbilayer movement promoted by SCR. All
measurements were made in the presence of
5 mM calcium. (D) Liposomes. (:) SCR proteoli-
posomes of DOPC/SM/Chol 2:1:1. (-) SCR
proteoliposomes of POPC/PS/Chol 9:1:3.3. (C)
SCR proteoliposomes of PC/PS 9:1. (B) SCR pro-
teoliposomes in the absence of Ca2þ. Average
values 5 SEM (nR 3).
Cholesterol Binding to scramblase 1389has a dual effect of helping in membrane insertion and in-
hibiting translocation.DISCUSSION
SCR, a 35 kDa protein, is an integral membrane protein that
is located in plasma membrane liquid-ordered domains
when it is palmitoylated. One of the major lipid components
in these domains is Chol, which increases the membrane
thickness of the plasma membrane to accommodate the
TMDs of many proteins. However, Chol can also interact
directly with these protein domains via hydrophobic or
van der Waals forces, as described for caveolin-1 and human
acetylcholine receptor TMDs (37,38). In this work, we pro-
vide evidence of a close relationship between Chol and
some TMD and extracellular coil amino acids of SCR
(Fig. 7) that would facilitate SCR accommodation and sta-
bilization in lo domains.FIGURE 7 Suggested outline of the SCR C-terminal domain disposition
in membranes when inserted into Chol-depleted domains (left) and Chol-
rich domains (right). Red, extracellular segment; green, the putative
TMD; blue, the cytoplasmic portion.Solid-phase binding and mono-/bilayer insertion
measurements
We performed a series of lipid interaction experiments with
the aim of studying peptide-induced membrane perturbation
and insertion. Similar results were obtained for SCR and
TM31C: the highest binding was observed for the sterols
that, like Chol, contain an alcohol group in ring A. The
Langmuir balance observation of increased TM31C affinity
for Chol deserves some comment (Fig. 3 A). The peptide
presents a preferential interaction with Chol-containing
membranes in comparison with pure PC. Even when lipidpacking (at 20 mol % Chol) is high due to the presence of
Chol, the peptide achieves insertion, and Dp rises from 4
to 6 mN/m. Thereafter, at very high Chol concentrations
(30–50 mol %), the lipid packing is too high for the peptide
to be included in the lipid film. The increase in surface pres-
sure is significantly smaller when the lipid film has no Chol
or when it is highly enriched in it, an effect that has been
observed with other proteins such as FraC and equinatoxin
II in PC/SM host lipid mixtures (39,40).
Addition of TM31C to liposomes made of PC/SM/Chol
(1:7:2) resulted in the gradual release of up to 40% of the
encapsulated solute (Fig. 3, B and C), with a fairly high
efflux rate. In comparison, with the same lipid composition,
but with 20 mol % Chol-one instead of Chol, the total ANTS
leakage was several times lower, with a very poor effluxBiophysical Journal 107(6) 1383–1392
1390 Posada et al.rate. Thus, the phase boundary between the ld and lo do-
mains appears to be important for SCR peptide insertion
and probably also for protein docking.Contribution of the SCR extracellular segment to
the interaction with Chol
DSC has been used to identify Chol-rich domains induced
by peptides or proteins containing a CRAC domain. The for-
mation of crystals of anhydrous Chol in the presence of
NAP-22 (41), caveolin-1 (16), or other peptides has been de-
tected by this technique. Two criteria must be taken into ac-
count as an indication of Chol recruitment into pools: 1), the
appearance of Chol crystals in a membrane in which Chol is
in principle miscible in the absence of peptides/proteins;
and 2), the recovery of the phase transition cooperativity
of the phospholipid partner.
It is rare for a protein not to discriminate between these
domains, but this does occur with caveolin-1 peptide (16),
which promotes Chol crystal formation but also stays in
the Chol-depleted domains, thus blurring the phospholipid
phase transition signal. This is also the case for the scram-
blase peptide TM31C (Fig. 4 A), which in contrast to
TM19 (Fig. 4 B) promotes Chol crystallite formation. How-
ever, both TM19 and the long peptide can be detected in
Chol-depleted pools abolishing the SOPC phase transition
at 6C (Fig. 4 C). This is evidenced by the fact that both pep-
tides lower the transition enthalpy of pure SOPC (Fig. 4 D),
just as they do that of DPPC and pSM (13).
Traditionally, SCR has been reconstituted in Chol-free
membranes, such that the C-terminal part of the protein
can be easily inserted. However, assuming that the amino
acid sequence [288K-E306] is the SCR TMD, the TMD rep-
resented by TM19 is too short to insert into Chol-rich mem-
branes, suggesting an important role for the extracellular
juxtamembrane amino acids in the interaction with Chol.
This phenomenon is not exceptional. A juxtamembrane
segment found in the gp41 protein of HIV is believed to
play a role in sequestering the whole protein to a Chol-
rich domain (42). In addition, certain amino acids involved
in CRAC or CARC domains are found outside or shared be-
tween the TMD and the extracellular portions, as is the case
with the nicotinic acetylcholine receptor protein TMDs (38)
and the translocator protein 18 kDa of the mitochondrial
outer membrane (43), thus supporting the involvement of
extramembranous amino acid residues in Chol interactions.
Using molecular modeling, we predicted that Chol would
be docked onto the sequence 298[FLIDFMFFESTGSQ]311,
with a favorable total energy of interaction of 64.39
KJ.mol1 (Fig. 5 A). Most of the interaction involves amino
acid residues that traditionally have not been predicted to be
involved in this binding. On the contrary, the modeling ex-
cludes other attractive amino acids. The strongest predicted
interaction with Chol cycles relies on TMD Leu299 and
Met303 via hydrophobic interactions with an energy of inter-Biophysical Journal 107(6) 1383–1392action of 5 KJ/mol per residue, which is fully consistent
with this type of interaction. Additionally, Glu306 and the
juxtamembrane polar amino acids Ser307, Ser310, and
Gln311, which would be located at the membrane interface
(34), also appear to interact strongly with Chol.The Chol ordering effect decreases SCR activity
Some lipid compositions that give rise to Chol-rich domains
were tested for protein reconstitution. The scrambling activ-
ity was lower when Chol was present in the membrane
(Fig. 6, C and D), showing that the Chol ordering effect
hampers the transbilayer distribution of lipids, in agreement
with other studies (44–46).
Zhao et al. (36) hypothesized that palmitoylation, apart
from anchoring the protein to the membrane, assists the
protein calcium-binding domain in forming the loop config-
uration required to complex the metal ion. We propose that
when the protein properly binds calcium, the SCR TMD
backbone dynamics could provide a hydrophilic pathway
along which a polar lipid headgroup could transverse the
bilayer (47). Alternatively, it could disorder the bilayer at
the helix/lipid interface for a more favorable translocation
(48).
How can SCR perform its scrambling role when it is
embedded in liquid-ordered domains? Although many pro-
teins and receptors are localized to lo domains, the effect
of ligand on this association is highly variable. In the case
of EGFR, which colocalizes with SCR in rafts (9), the pro-
tein rapidly moves out from lipid rafts upon activation by
ligand (49). For this receptor, events such as ligand binding,
dimerization, and autophosphorylation are all enhanced af-
ter raft disruption occurs (50–52). Thus, apart from serving
in signal initiation, rafts may also be important platforms for
suppressing false signaling coming from proteins such as
EGFR and perhaps SCR. SCR anchored to lipid rafts serves
as an important effector for cell proliferation and maturation
(53) by promoting, among other effects, the kinase activity
of cellular c-Src. It is therefore conceivable that SCR could
modulate its activities by its localization in the cell,
including its role as a transcription factor in the nucleus
(4,54) and its possible migration from rafts to the bulk of
the plasma membrane or to the lo/ld interface to promote
lipid scrambling.SCR palmitoylated and anchored to Chol-rich
membranes
The notion of scramblase anchoring to the membrane was
challenged by Bateman et al. (7), who proposed that the
highly hydrophobic a-helical domain would remain buried
in the protein core, with the palmitoyl residues serving as
the only tether to the bilayer. Our previous experimental
work (13) provided strong evidence that the 288–306 pep-
tide SCR could be membrane inserted. We also detected
Cholesterol Binding to scramblase 1391an affinity of TM31C for liquid-ordered (lo) domains, and
more specifically for phase boundaries limiting lo domains.
Palmitoylation is important for protein sorting into mem-
brane rafts, as demonstrated for members of the Src family
in cells (55) and for G-proteins in model membranes (56).
The packing order conferred by the structure of the lipid
modification is considered to be an important determinant
for a protein to be targeted to a Chol-rich domain, rather
than the TMD amino acid composition or hydrophobic
mismatch prevention (31).
In the case of SCR, palmitoylation functions primarily as a
sorting signal (8) that is required for its plasma membrane
transport and for subsequent anchoring to Chol-enriched
domains. However, protein TMD might also be involved in
anchoring SCR to Chol-rich membranes. Our data are
consistent with the hypothesis of direct lipid-protein contact,
with all of the tested methods showing large, measurable
SCR-Chol interactions. We propose that both palmitoylation
and the protein amino acid segment [298F-Q311] anchor SCR
to Chol-rich membranes (Fig. 7). Additionally, Chol inhibits
protein scrambling activity by ordering the membrane
around the TMD. Calcium binding could stimulate the
proper conformation of TMD to promote lipid flip-flop.
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